| Literature DB >> 28007846 |
Makoto Kurano1,2, Kuniyuki Kano2,3, Tomotaka Dohi4, Hirotaka Matsumoto3, Koji Igarashi5, Masako Nishikawa1,2, Ryunosuke Ohkawa6, Hitoshi Ikeda1,2,6, Katsumi Miyauchi4, Hiroyuki Daida4, Junken Aoki2,3, Yutaka Yatomi7,2,6.
Abstract
Lysophosphatidic acids (LysoPAs) and lysophosphatidylserine (LysoPS) are emerging lipid mediators proposed to be involved in the pathogenesis of acute coronary syndrome (ACS). In this study, we attempted to elucidate how LysoPA and LysoPS become elevated in ACS using human blood samples collected simultaneously from culprit coronary arteries and peripheral arteries in ACS subjects. We found that: 1) the plasma LysoPA, LysoPS, and lysophosphatidylglycerol levels were not different, while the lysophosphatidylcholine (LysoPC), lysophosphatidylinositol, and lysophosphatidylethanolamine (LysoPE) levels were significantly lower in the culprit coronary arteries; 2) the serum autotaxin (ATX) level was lower and the serum phosphatidylserine-specific phospholipase A1 (PS-PLA1) level was higher in the culprit coronary arteries; 3) the LysoPE and ATX levels were significant explanatory factors for the mainly elevated species of LysoPA, except for 22:6 LysoPA, in the peripheral arteries, while the LysoPC and LysoPE levels, but not the ATX level, were explanatory factors in the culprit coronary arteries; and 4) 18:0 and 18:1 LysoPS were significantly correlated with PS-PLA1 only in the culprit coronary arteries. In conclusion, the origins of LysoPA and LysoPS might differ between culprit coronary arteries and peripheral arteries, and substrates for ATX, such as LysoPC and LysoPE, might be important for the generation of LysoPA in ACS.Entities:
Keywords: acute coronary disease; lysophosphatidic acids; lysophosphatidylcholine; lysophosphatidylethanolamine; lysophosphatidylserine
Mesh:
Substances:
Year: 2016 PMID: 28007846 PMCID: PMC5282959 DOI: 10.1194/jlr.P071803
Source DB: PubMed Journal: J Lipid Res ISSN: 0022-2275 Impact factor: 5.922